Sofia Medrano1, Amal Abdel-Baki1, Emmanuel Stip1, Stéphane Potvin1. 1. Medrano, MD, Clinique JAP, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada, and CHUM research centre, Montreal, Quebec, Canada. Abdel-Baki, MD, MSc, Clinique JAP, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada, Department of Psychiatry, Université de Montréal, Montreal, Quebec, Canada, and CHUM research centre, Montreal, Quebec, Canada. Stip, MD, and Potvin, PhD, Department of Psychiatry, Université de Montréal, Montreal, Quebec, Canada, and Centre de recherche Fernand-Séguin, Institut universitaire en santé mentale de Montréal, Montreal, Quebec, Canada.
Abstract
Abstract: Poor adherence to antipsychotics, which affects outcome, is frequent in first episode psychosis (FEP). Most randomized studies demonstrate no superiority of long-acting injectable antipsychotics (LAI-AP) over oral antipsychotics (OAP). However, participants in these studies represent a minority of patients who may benefit from LAI-AP. Mirror and naturalistic studies generally demonstrate efficacy of LAI-AP on more representative samples, but studies on FEP are scarce. Aim: To describe LAI-AP's utilization and impact on FEP outcome in a naturalistic setting. Methods: A 3-year longitudinal prospective and retrospective descriptive study of all consecutive admissions from two Early Intervention Services for psychosis (EIS) in Montréal, Canada, compared the characteristics and evolution of patients who received LAI-AP for at least 12 months to those who received OAP only. Results: From 375 FEP patients included, 26,7% received LAI-AP during their follow-up. They were more likely to have poor prognostic factors (male gender, lower premorbid functioning, homelessness, substance use disorder and schizophrenia spectrum diagnoses). Despite a more severe illness and lower functioning in the LAI-AP group, at admission and study endpoint, clinical and functional improvements were observed. Conclusion: Early prescription of LAI-AP seems beneficial in FEP with poor prognostic factors.
Abstract: Poor adherence to antipsychotics, which affects outcome, is frequent in first episode psychosis (FEP). Most randomized studies demonstrate no superiority of long-acting injectable antipsychotics (LAI-AP) over oral antipsychotics (OAP). However, participants in these studies represent a minority of patients who may benefit from LAI-AP. Mirror and naturalistic studies generally demonstrate efficacy of LAI-AP on more representative samples, but studies on FEP are scarce. Aim: To describe LAI-AP's utilization and impact on FEP outcome in a naturalistic setting. Methods: A 3-year longitudinal prospective and retrospective descriptive study of all consecutive admissions from two Early Intervention Services for psychosis (EIS) in Montréal, Canada, compared the characteristics and evolution of patients who received LAI-AP for at least 12 months to those who received OAP only. Results: From 375 FEP patients included, 26,7% received LAI-AP during their follow-up. They were more likely to have poor prognostic factors (male gender, lower premorbid functioning, homelessness, substance use disorder and schizophrenia spectrum diagnoses). Despite a more severe illness and lower functioning in the LAI-AP group, at admission and study endpoint, clinical and functional improvements were observed. Conclusion: Early prescription of LAI-AP seems beneficial in FEP with poor prognostic factors.
Authors: Christoph U Correll; Leslie Citrome; Peter M Haddad; John Lauriello; Mark Olfson; Stephen M Calloway; John M Kane Journal: J Clin Psychiatry Date: 2016 Impact factor: 4.384
Authors: Andreas Schreiner; Kaire Aadamsoo; A Carlo Altamura; Manuel Franco; Philip Gorwood; Nikolaj G Neznanov; Juan Schronen; Alp Ucok; Mathias Zink; Adam Janik; Pierre Cherubin; Marjolein Lahaye; Ludger Hargarter Journal: Schizophr Res Date: 2015-10-01 Impact factor: 4.939
Authors: M A Roy; G Lanctôt; C Mérette; D Cliche; J P Fournier; P Boutin; C Rodrigue; L Charron; M Turgeon; M Hamel; N Montgrain; L Nicole; A Pirès; H Wallot; A M Ponton; Y Garneau; C Dion; J C Lavallée; A Potvin; P Szatmari; M Maziade Journal: Am J Psychiatry Date: 1997-12 Impact factor: 18.112
Authors: J Peuskens; J M Olivares; J Pecenak; I Tuma; H Bij de Weg; L Eriksson; S Resseler; K Akhras; A Jacobs Journal: Curr Med Res Opin Date: 2010-03 Impact factor: 2.580
Authors: Robin Emsley; Petrus Oosthuizen; Liezl Koen; Dana J H Niehaus; Rossella Medori; Jonathan Rabinowitz Journal: Clin Ther Date: 2008-12 Impact factor: 3.393